Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Suptavumab (REGN2222) Formulations in Healthy Adults
NCT02828397Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suptavumab in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Serum REGN2222 concentration-time curve and Peak REGN2222 concentration. Started Apr 2016; status: completed.
02
Drugs
suptavumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02828397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828397.